Clearstead Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Clearstead Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$827	Sell	41 -991	-96%	-$26.6K	﹤0.01%	2711
2026 Q2	$26.1K	Buy	1,032 +32	+3%	+$704	﹤0.01%	1714
2026 Q1	$22.3K	Sell	1,000 -17	-2%	-$406	﹤0.01%	1434
2025 Q4	$27.2K	Sell	1,017 -257	-20%	-$6.14K	﹤0.01%	1618
2025 Q3	$27.2K	Buy	1,274 +271	+27%	+$6.41K	﹤0.01%	1504
2025 Q2	$21.6K	Buy	1,003 +3	+0.3%	+$56	﹤0.01%	1588
2025 Q1	$16.6K	Hold	1,000	–	–	﹤0.01%	1473
2024 Q4	$18.4K	Hold	1,000	–	–	﹤0.01%	1415
2024 Q3	$15.4K	Hold	1,000	–	–	﹤0.01%	1494
2024 Q2	$16.2K	Hold	1,000	–	–	﹤0.01%	1436
2024 Q1	$15.2K	Hold	1,000	–	–	﹤0.01%	989
2023 Q4	$31.3K	Hold	1,000	–	–	﹤0.01%	857
2023 Q3	$20.8K	Hold	1,000	–	–	﹤0.01%	885
2023 Q2	$24K	Hold	1,000	–	–	﹤0.01%	871
2023 Q1	$18.8K	Hold	1,000	–	–	﹤0.01%	862
2022 Q4	$15.9K	Hold	1,000	–	–	﹤0.01%	836
2022 Q3	$16K	Hold	1,000	–	–	﹤0.01%	805
2022 Q2	$14K	Hold	1,000	–	–	﹤0.01%	864
2022 Q1	$24K	Hold	1,000	–	–	﹤0.01%	820
2021 Q4	$23K	Sell	1,000 -508	-34%	-$10.2K	﹤0.01%	790
2021 Q3	$25K	Hold	1,508	–	–	﹤0.01%	739
2021 Q2	$37K	Hold	1,508	–	–	﹤0.01%	601
2021 Q1	$39K	Hold	1,508	–	–	﹤0.01%	579
2020 Q4	$81K	Hold	1,508	–	–	0.01%	448
2020 Q3	$62K	Buy	1,508 +1,008	+202%	+$43.5K	0.01%	435
2020 Q2	$24K	Hold	500	–	–	﹤0.01%	509
2020 Q1	$21K	Buy	+500	New	+$20.6K	﹤0.01%	498

Other funds holding ACAD

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Clearstead Advisors's ACAD Position: Q3 2026 in Review

Clearstead Advisors reduced its Acadia Pharmaceuticals (ACAD) stake by 96% in Q3 2026, selling an estimated $26.6K and leaving 41 shares worth $827. The position accounts for ﹤0.01% of the portfolio, ranked #2711.

Clearstead Advisors first reported a position in ACAD in Q1 2020 and has held it in 27 quarters since. The position peaked at $81K in Q4 2020. 137 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

Clearstead Advisors held 41 shares of Acadia Pharmaceuticals worth $827 as of Q3 2026.
Clearstead Advisors sold 991 Acadia Pharmaceuticals shares in Q3 2026, an estimated $26.6K.
Acadia Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q3 2026, its #2711 holding.
Clearstead Advisors first reported a position in Acadia Pharmaceuticals in Q1 2020 and has held it in 27 quarters since.
Clearstead Advisors's Acadia Pharmaceuticals position peaked at $81K in Q4 2020.
137 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Clearstead Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.